Search This Blog

Friday, January 24, 2020

Intuitive Surgical down 4% after Q4 repor

Sell-side analysts weigh in after Intuitive Surgical (ISRG -4.1%) reported Q4 and 2019 results after the close yesterday.
Evercore ISI’s Vijay Kumar (Neutral): Gross margin guide for this year (will “fluctuate” according to CFO Marshall Mohr, 70 – 71% versus 72.2% last quarter) implicitly assuming geographical skew towards U.S. Price target cut to $595 from $600.
SVB Leerink’s Richard Newitter (Outperform/$670): Guidance “probably conservative” leaving room for share appreciation.
Cantor Fitzgerald’s Craig Bijou (Overweight/$690): Continued investment in imaging and analytics capability could slow EPS growth, but fundamentals remain strong.
https://seekingalpha.com/news/3534386-intuitive-surgical-down-4-after-q4-report

Key events next week – healthcare

Noteworthy events during the week of January 26 – February 1 for healthcare investors.
MONDAY (1/27): European Medicines Agency advisory group CHMP monthly agenda due.
TUESDAY (1/28): ASM Biothreats Conference, Arlington, VA (3 days). Tonix Pharmaceuticals (NASDAQ:TNXP): Preclinical data on synthetic chimeric horsepox virus vaccine.
PARP and DDR Inhibitors Summit, Boston (3 days).
Annovis Bio (ANVS): IPO expected to price.
WEDNESDAY (1/29): Tabula Rasa HealthCare (NASDAQ:TRHC): Investor & Analyst Day, NYC.
Black Diamond Therapeutics (BDTX): IPO expected to price.
Avadim Health (AHI): IPO expected to price.
BioCardia (OTCQB:BCDA): IPO lockup expires.
THURSDAY (1/30): T-cell Lymphoma Forum, La Jolla, CA (3 days).
1Life Healthcare (ONEM): IPO expected to price.
Arcutis Biotherapeutics (ARQT): IPO expected to price.
FRIDAY (1/31): Approximate FDA action date for Aimmune Therapeutics‘ (NASDAQ:AIMT) Palforzia (AR101) for peanut allergy.
https://seekingalpha.com/news/3534323-key-events-next-week-healthcare

Parties unite over Taiwan’s exclusion from WHO anti-virus planning

Taiwan’s exclusion from World Health Organization meetings on the coronavirus outbreak has united the island’s political parties, who normally agree on little, especially to do with China.
Taiwan is not a member of the WHO due to the objection of China, which considers it a Chinese province with no right to participate in international organizations as a separate entity.
Taiwan was not allowed to participate in an emergency WHO meeting on Wednesday about the new virus, which has killed at least 25 people since originating in the Chinese city of Wuhan last month.
Taiwan has reported three cases, two of which it only confirmed on Friday – a Chinese tourist and a Taiwanese businessman who had returned to the island from China.
Taiwan President Tsai Ing-wen, re-elected by a landslide this month on a platform of standing up to China, this week called on the WHO to set aside political considerations and grant it full access to virus updates.
“Taiwan is at the forefront of global epidemic prevention. There needs to be room at the WHO for Taiwan’s participation,” she told reporters.
Taiwan’s main opposition party, the Kuomintang, which favors close ties with China, expressed its anger saying that epidemic prevention should know no boundaries.
“Please could the WHO cast aside political considerations. If Taiwan is alone in being left out of epidemic prevention work it will leave a gap, and is not beneficial to promoting epidemic prevention work around the world,” it said in a statement.
Taipei Mayor Ko Wen-je, a doctor by training who is no friend of either Tsai’s Democratic Progressive Party nor the Kuomintang, added his voice of disapproval.
“In recent years, Taiwan has been placed outside the world’s epidemic prevention system, and has no way of getting first hand information. This is a problem,” said Ko, whose Taiwan People’s Party won its first parliamentary seats this month.
China says such concerns are nonsense. China’s foreign ministry said this week nobody cares more about Taiwan’s people than China’s central government.
Taiwan’s Centres for Disease Control also say they have smooth channels with China, though it has also complained about its inability to get first hand information from the WHO.

Mike Ryan, executive director of the WHO emergencies programme, told a news conference in Geneva on Thursday they work closely with technical partners in what he termed “China, Taiwan”.
“And I believe the authorities in Taiwan are working very closely with China in the mainland and I believe there have been joint missions and joint approaches to the response,” he said.
https://www.reuters.com/article/us-china-health-taiwan/parties-unite-over-taiwans-exclusion-from-who-anti-virus-planning-idUSKBN1ZN0QG

Neovasc up on advancement of new valve

Nano cap Neovasc (NASDAQ:NVCN) is up 6% premarket on increased volume in reaction to its announcement that it has finalized the design concept for a fully retrievable transfemoral trans-septal Tiara heart valve that includes a lower profile and steerable delivery system.
Development will now proceed into a design freeze phase review.
https://seekingalpha.com/news/3534356-neovasc-up-6-premarket-on-advancement-of-new-valve

High-tech robot doctor treats first US coronavirus patient

The first US patient to contract the deadly coronavirus is being treated by a robot doctor in a tiny secured room to reduce the risk of the disease spreading, according to a report.
Decked out with a stethoscope, camera and microphone, the cutting-edge automaton has been tending to the 30-something man in a 20-by-20-foot “isopod” at Providence Regional Medical Center in Everett, Wash., a hospital chief told The Guardian.
The unnamed patient — who recently returned from a trip to central China — was picked up at his home, taken to the hospital by ambulance and placed in the closed isolation unit Monday, according to Dr. George Diaz, chief of infectious diseases.
Once the room was secured, Diaz said he sat outside the window to operate the futuristic physician in order to avoid coming in contact with the disease.
The patient, who is in “satisfactory condition,” was allowed to move around inside the pod once it was secured, Diaz said.
It’s the first time the medical center has admitted someone into its special pathogens unit, which was built in 2015 as a response to the Ebola virus.
“The wheels were greased enough that it wasn’t hard to get the process rolling to activate all the procedures that we had put in place,” Diaz said. “Every few weeks [we’re] doing drills and training like you would for an earthquake or fire drill or something like that, and so you’re always trying to maintain a state of readiness.
The virus, which is believed to have originated in Wuhan, in Hubei province, has killed at least 17 people in China and infected hundreds more.
The World Health Organization has been considering declaring a public health emergency but CDC officials say the risk of contracting the disease in the US is low.
https://nypost.com/2020/01/23/high-tech-robot-doctor-treats-first-us-coronavirus-patient/

Alpine Immune Sciences up on encouraging data on lead candidate

Thinly traded nano cap Alpine Immune Sciences (NASDAQ:ALPN) is up 8% premarket, albeit on only 1,008 shares, on the heels of new preclinical data on lead candidate ALPN-101. The results were presented at the Crohn’s & Colitis Congress in Austin, TX.
In a T cell transfer model of chronic inflammatory bowel disease (IBD), ALPN-101 showed “superior” suppression of proinflammatory cytokines in vitro compared to single CD28 or ICOS pathway inhibitors in peripheral blood mononuclear cells from a colitis patient. It also showed effector memory T cell and cytokine suppression in mouse models of IBD.
ALPN-101 is a dual CD28/ICOS antagonist also in development for graft-versus-host disease.
https://seekingalpha.com/news/3534340-alpine-immune-sciences-up-8-premarket-on-encouraging-data-on-lead-candidate

Sonoma Pharma up 20% premarket on potential sale of U.S. dermatology unit

Thinly traded nano cap Sonoma Pharmaceuticals (NASDAQ:SNOA) has engaged Maxim Group LLC to assist in exploring strategic alternatives for its U.S. Dermatology Division.
Shares up 20% premarket on average volume.
https://seekingalpha.com/news/3534326-sonoma-pharma-up-20-premarket-on-potential-sale-of-u-s-dermatology-unit